Summary of PolyBio Spring 2024 Symposium

Researchers discussed their work on understanding the persistence of SARS-CoV-2 and its impact on long COVID. They explored viral persistence, immune responses in long COVID patients, and the potential role of the lung microbiome. Their findings may help elucidate the causes of long COVID and inform potential treatments.


  • :test_tube: Researchers discussed viral persistence in platelets and megakaryocytes (which make platelets), potentially forming a reservoir contributing to long COVID symptoms.
  • :thermometer: The immune response in long COVID patients, including the presence of Spike protein and viral RNA in megakaryocytes and platelets, was explored.
  • :lungs: The role of the lung microbiome in long COVID was studied, emphasizing its potential impact on the condition.
  • :dna: Alterations in germinal center responses and reduced neutralizing antibodies were observed in long COVID patients.
  • :thermometer: Individuals with long COVID showed higher levels of nucleocapsid protein antibodies and lower neutralizing titers against ancestral and Omicron variants, particularly in females.
  • :test_tube: The impact of SARS-CoV-2 infection on the development and progression of Alzheimer’s disease was investigated using ‘cerebral organoids’, which are artificially grown tissue resembling parts of the human brain.
  • :thermometer: Saliva samples from individuals with long COVID revealed ongoing immune dysfunction and the potential role of the salivary microbiome in modulating immune responses.

Key Insights

  • :test_tube: Identifying subtypes of long COVID through machine learning techniques can aid in personalized treatment approaches and better understanding the heterogeneity of the condition.
  • :spider: The potential reactivation of tickborne and vectorborne illnesses in long COVID patients underscores the need for comprehensive medical assessments and treatment strategies tailored to individual cases.

NOTE: This summary was generated via AI so it may not be accurate.

The whole Youtube video

Warning: the ‘science’ may be unreliable

Um… they are having straight-faced discussions about microclots. ME/CFS and Long COVID patients were trying triple anticoag in 2022 and it hasn’t worked. The science on microclots is not very promising because many healthy controls have them (elevated levels of microclots) and some Long COVID patients do not have them.